EU Approves AstraZeneca Trixeo Asthma Therapy
Analysis based on 11 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026
The approval modestly strengthens AstraZeneca's respiratory franchise by opening an additional EU indication for an already-marketed product, supporting incremental revenue with limited new development cost. Market reaction is likely muted because the decision was widely anticipated after the CHMP positive opinion, though it reinforces the company's growth outlook in BioPharmaceuticals.
The International — European Commission approved AstraZeneca's Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) as a maintenance treatment for asthma in patients aged 12 years and older whose disease is not adequately controlled by a medium-dose inhaled corticosteroid plus a long-acting beta2-agonist. The decision follows a positive opinion from the European Union — Committee for Medicinal Products for Human Use of the European Union — European Medicines Agency and is based on the Phase III KALOS and LOGOS trials, which showed statistically significant improvements in lung function versus ICS/LABA comparators and, in a pooled analysis, a significant reduction in the annualised rate of severe asthma exacerbations. Trixeo becomes the first and only triple-combination therapy approved in the European Union for this patient population regardless of exacerbation history. The medicine, marketed as Breztri Aerosphere in the United States, China and Japan, is already approved for asthma in the United States and Japan and remains under review in China and other markets; it is also approved for COPD in more than 90 countries. AstraZeneca executives Ruud Dobber and investigator Alberto Papi of the University of Ferrara highlighted the unmet need among the nearly 43 million people with asthma in Europe. The approval expands AstraZeneca's respiratory portfolio and adds a new revenue stream in the EU.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard